Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 05 Aug 2022
FDA approves first targeted therapy for HER2 low breast cancer
5 August 2022 - Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an intravenous infusion for the treatment of ...
Posted by Michael Wonder on 05 Aug 2022
Calquence tablet formulation approved in the US across current indications
5 August 2022 - New formulation can be co-administered with gastric acid-reducing agents. ...
Posted by Michael Wonder on 05 Aug 2022
Acadia Pharmaceuticals receives complete response letter from U.S. FDA for supplemental new drug application for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis
4 August 2022 - Acadia Pharmaceuticals today announced that the company has received a complete response letter from the U.S. ...
Posted by Michael Wonder on 05 Aug 2022
Australia secures new third generation monkeypox virus vaccine
4 August 2022 - The Albanese Government has secured 450,000 doses of the new third generation monkeypox virus vaccine by Bavarian ...
Posted by Michael Wonder on 04 Aug 2022
U.S. regulators defend requiring more data on monkeypox drug
4 August 2022 - As U.S. monkeypox cases rise, U.S. health agencies in a medical journal article published on Wednesday ...
Posted by Michael Wonder on 04 Aug 2022
The patient voice – the value of patient-reported outcomes in HTA
4 August 2022 - The patient’s voice is increasingly important in securing access for therapies in markets and demonstrating how ...
Posted by Michael Wonder on 04 Aug 2022
Advanced oesophageal carcinoma: nivolumab in combination with chemotherapy or ipilimumab prolongs life compared to chemotherapy alone
1 August 2022 - The additional clinical benefit cannot be quantified because the data on health status and health-related quality ...
Posted by Michael Wonder on 04 Aug 2022
Regression models for ordinal outcomes
4 August 2022 - Ordinal logistic regression models are tailored for the analysis of ordinal outcomes. ...
Posted by Michael Wonder on 04 Aug 2022
Vaxcyte provides positive regulatory updates for VAX-24 adult and paediatric programs
4 August 2022 - Company receives FDA fast track designation for VAX-24 in adults. ...
Posted by Michael Wonder on 04 Aug 2022
Bulk billing ‘on verge of collapse’
5 August 2022 - Doctors have warned that the nation is facing the “collapse of bulk billing” in general practice, ...
Posted by Michael Wonder on 04 Aug 2022
ICER publishes evidence report on treatments for amyotrophic lateral sclerosis
4 August 2022 - Given current data, AMX0035 is comparable or better to standard of care; AMX0035 would achieve common thresholds ...
Posted by Michael Wonder on 04 Aug 2022
U.S. prescription drug pricing doesn’t favour the patient: case of sub-optimal market for cancer pharmaceuticals
3 August 2022 - The high costs of cancer drugs impact patients negatively. In fact, the out of pocket cost ...
Posted by Michael Wonder on 04 Aug 2022
Panicked patients as popular medications get wiped from pharmacy shelves
4 August 2022 - Widely used medications — including one used to treat ADHD — are missing from Australian shelves amid ...
Posted by Michael Wonder on 04 Aug 2022
Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA mutated HER2 negative high-risk early breast cancer
4 August 2022 - First and only approved medicine targeting BRCA mutations in early breast cancer ...
Posted by Michael Wonder on 04 Aug 2022
Travere Therapeutics provides regulatory updates on its development programs
3 August 2022 - Pegtibatinase granted breakthrough therapy designation by FDA. ...